Tegaserod (Zelnorm) for irritable bowel syndrome

Tegaserod (Zelnorm) for irritable bowel syndrome

Tegaserod (Zelnorm) is the first treatment approved by the US Food and Drug Administration for the short-term management of constipation-predominant irritable bowel syndrome (IBS) in women. A partial agonist of serotonin subtype-4 receptors, tegaserod stimulates peristalsis, increases intestinal sec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American family physician 2004-01, Vol.69 (2), p.363
1. Verfasser: DeYoung, G Robert
Format: Artikel
Sprache:eng
Schlagworte:
Bowel disease
Female
Humans
Indoles - adverse effects
Indoles - economics
Irritable Bowel Syndrome - drug therapy
Medical treatment
Prescription drugs
Serotonin Receptor Agonists - adverse effects
Serotonin Receptor Agonists - economics
Women
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 2
container_start_page 363
container_title American family physician
container_volume 69
creator DeYoung, G Robert
description Tegaserod (Zelnorm) is the first treatment approved by the US Food and Drug Administration for the short-term management of constipation-predominant irritable bowel syndrome (IBS) in women. A partial agonist of serotonin subtype-4 receptors, tegaserod stimulates peristalsis, increases intestinal secretion, and may alter associated pain. In contrast, alosetron (Lotronex) is available under restricted conditions of use for diarrhea-predominant IBS.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_234288406</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>535260741</sourcerecordid><originalsourceid>FETCH-LOGICAL-p234t-9f8e9c9139d2db1b098dd4523ed12431ffffaf80949379ad92f1d2850a82d3a73</originalsourceid><addsrcrecordid>eNo1j01LAzEYhHNQbK3-BQme9LCQr22SoxS1QsFLBfGyJL5vZMvuZk12kf57A9a5DAMPM8wZWTLGRGWkeV-Qy5wPJeqa2wuy4Eqva63NkrA9frmMKQK9-8BuiKm_pyEm2qbUTs53SH38wY7m4wAp9nhFzoPrMl6ffEXenh73m221e31-2TzsqlFINVU2GLSflksLAjz3zBoAVQuJwIWSPBS5YJhVVmrrwIrAQZiaOSNAOi1X5Pavd0zxe8Y8NYc4p6FMNmVAGKPYukA3J2j2PUIzprZ36dj8_5O_fOBJ5Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>234288406</pqid></control><display><type>article</type><title>Tegaserod (Zelnorm) for irritable bowel syndrome</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>DeYoung, G Robert</creator><creatorcontrib>DeYoung, G Robert</creatorcontrib><description>Tegaserod (Zelnorm) is the first treatment approved by the US Food and Drug Administration for the short-term management of constipation-predominant irritable bowel syndrome (IBS) in women. A partial agonist of serotonin subtype-4 receptors, tegaserod stimulates peristalsis, increases intestinal secretion, and may alter associated pain. In contrast, alosetron (Lotronex) is available under restricted conditions of use for diarrhea-predominant IBS.</description><identifier>ISSN: 0002-838X</identifier><identifier>PMID: 14765778</identifier><identifier>CODEN: AFPYBF</identifier><language>eng</language><publisher>United States: American Academy of Family Physicians</publisher><subject>Bowel disease ; Female ; Humans ; Indoles - adverse effects ; Indoles - economics ; Irritable Bowel Syndrome - drug therapy ; Medical treatment ; Prescription drugs ; Serotonin Receptor Agonists - adverse effects ; Serotonin Receptor Agonists - economics ; Women</subject><ispartof>American family physician, 2004-01, Vol.69 (2), p.363</ispartof><rights>Copyright American Academy of Family Physicians Jan 15, 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14765778$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DeYoung, G Robert</creatorcontrib><title>Tegaserod (Zelnorm) for irritable bowel syndrome</title><title>American family physician</title><addtitle>Am Fam Physician</addtitle><description>Tegaserod (Zelnorm) is the first treatment approved by the US Food and Drug Administration for the short-term management of constipation-predominant irritable bowel syndrome (IBS) in women. A partial agonist of serotonin subtype-4 receptors, tegaserod stimulates peristalsis, increases intestinal secretion, and may alter associated pain. In contrast, alosetron (Lotronex) is available under restricted conditions of use for diarrhea-predominant IBS.</description><subject>Bowel disease</subject><subject>Female</subject><subject>Humans</subject><subject>Indoles - adverse effects</subject><subject>Indoles - economics</subject><subject>Irritable Bowel Syndrome - drug therapy</subject><subject>Medical treatment</subject><subject>Prescription drugs</subject><subject>Serotonin Receptor Agonists - adverse effects</subject><subject>Serotonin Receptor Agonists - economics</subject><subject>Women</subject><issn>0002-838X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo1j01LAzEYhHNQbK3-BQme9LCQr22SoxS1QsFLBfGyJL5vZMvuZk12kf57A9a5DAMPM8wZWTLGRGWkeV-Qy5wPJeqa2wuy4Eqva63NkrA9frmMKQK9-8BuiKm_pyEm2qbUTs53SH38wY7m4wAp9nhFzoPrMl6ffEXenh73m221e31-2TzsqlFINVU2GLSflksLAjz3zBoAVQuJwIWSPBS5YJhVVmrrwIrAQZiaOSNAOi1X5Pavd0zxe8Y8NYc4p6FMNmVAGKPYukA3J2j2PUIzprZ36dj8_5O_fOBJ5Q</recordid><startdate>20040115</startdate><enddate>20040115</enddate><creator>DeYoung, G Robert</creator><general>American Academy of Family Physicians</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20040115</creationdate><title>Tegaserod (Zelnorm) for irritable bowel syndrome</title><author>DeYoung, G Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p234t-9f8e9c9139d2db1b098dd4523ed12431ffffaf80949379ad92f1d2850a82d3a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Bowel disease</topic><topic>Female</topic><topic>Humans</topic><topic>Indoles - adverse effects</topic><topic>Indoles - economics</topic><topic>Irritable Bowel Syndrome - drug therapy</topic><topic>Medical treatment</topic><topic>Prescription drugs</topic><topic>Serotonin Receptor Agonists - adverse effects</topic><topic>Serotonin Receptor Agonists - economics</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DeYoung, G Robert</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American family physician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DeYoung, G Robert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tegaserod (Zelnorm) for irritable bowel syndrome</atitle><jtitle>American family physician</jtitle><addtitle>Am Fam Physician</addtitle><date>2004-01-15</date><risdate>2004</risdate><volume>69</volume><issue>2</issue><spage>363</spage><pages>363-</pages><issn>0002-838X</issn><coden>AFPYBF</coden><abstract>Tegaserod (Zelnorm) is the first treatment approved by the US Food and Drug Administration for the short-term management of constipation-predominant irritable bowel syndrome (IBS) in women. A partial agonist of serotonin subtype-4 receptors, tegaserod stimulates peristalsis, increases intestinal secretion, and may alter associated pain. In contrast, alosetron (Lotronex) is available under restricted conditions of use for diarrhea-predominant IBS.</abstract><cop>United States</cop><pub>American Academy of Family Physicians</pub><pmid>14765778</pmid></addata></record>
fulltext fulltext
identifier ISSN: 0002-838X
ispartof American family physician, 2004-01, Vol.69 (2), p.363
issn 0002-838X
language eng
recordid cdi_proquest_journals_234288406
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Bowel disease
Female
Humans
Indoles - adverse effects
Indoles - economics
Irritable Bowel Syndrome - drug therapy
Medical treatment
Prescription drugs
Serotonin Receptor Agonists - adverse effects
Serotonin Receptor Agonists - economics
Women
title Tegaserod (Zelnorm) for irritable bowel syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T16%3A34%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tegaserod%20(Zelnorm)%20for%20irritable%20bowel%20syndrome&rft.jtitle=American%20family%20physician&rft.au=DeYoung,%20G%20Robert&rft.date=2004-01-15&rft.volume=69&rft.issue=2&rft.spage=363&rft.pages=363-&rft.issn=0002-838X&rft.coden=AFPYBF&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E535260741%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=234288406&rft_id=info:pmid/14765778&rfr_iscdi=true